Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Update - April 2016

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Alendronic acid effervescent tablets (Binosto®) have been accepted for restricted use in the treatment of postmenopausal osteoporosis. The restriction limits use to patients who are unable to swallow tablets where alendronic acid is the appropriate treatment choice.

Camellia sinensis (Catephen®) has been accepted for restricted use in the cutaneous treatment of external genital and perianal warts (condylomata acuminata) in immunocompetent patients from the age of 18 years. The restriction limits use to patients not suitable for podophyllotoxin or who have not responded to treatment with podophyllotoxin.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - April 2016' on Email Share 'SMC Update - April 2016' on Delicious Share 'SMC Update - April 2016' on Digg Share 'SMC Update - April 2016' on Facebook Share 'SMC Update - April 2016' on Google+ Share 'SMC Update - April 2016' on reddit Share 'SMC Update - April 2016' on StumbleUpon Share 'SMC Update - April 2016' on Twitter

atomic-wealth

No Comments to “SMC Update - April 2016”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 788,922 spam comments.

atomic-wealth
fond-illness
summer